LONDON, March 16, 2026, 17:25 GMT
- GSK shares ended 0.25% lower at 2,026 pence on Monday. 1
- A company filing showed GSK bought back 445,000 shares on March 13 at an average 2,041.70 pence. 2
- Investors are weighing shareholder returns against slower 2026 growth and uncertainty in vaccines. 3
GSK shares slipped on Monday even after the British drugmaker disclosed another round of purchases under its buyback plan, a sign investors still want a bigger operating trigger. The London-listed shares ended 0.25% lower at 2,026 pence, below the 2,041.70 pence average price GSK paid for stock bought on March 13, market data and a company filing showed. 1
The move matters because GSK is trying to hold investor confidence as growth cools from last year and newer products take on more of the burden. Buybacks can lift earnings per share — profit spread across a smaller share count — but they do not settle the bigger question of whether launches and dealmaking can offset pressure in older businesses. 3
Monday’s filing showed GSK repurchased 445,000 ordinary shares on March 13, with prices ranging from 2,027 pence to 2,060 pence. After the purchase, GSK said it held 249.8 million shares in treasury, meaning shares kept on the company’s own books, equal to 6.14% of voting rights. 2
Those trades sit inside the fourth phase of GSK’s 2 billion-pound buyback. The company said on Feb. 17 that this tranche would cover up to 450 million pounds of purchases through April 24 and was intended to return excess capital to shareholders while enhancing earnings per share. 3
The share-count story is only part of the investment case. On March 13, the U.S. Food and Drug Administration widened approval for GSK’s RSV vaccine, Arexvy, to cover at-risk adults aged 18 to 49, opening a new segment where it will compete with Moderna’s mRESVIA and Pfizer’s Abrysvo once the U.S. Centers for Disease Control and Prevention gives a recommendation for that age group. 4
GSK’s stock had already rallied hard before Monday. On Feb. 4, after new CEO Luke Miels backed a target of more than 40 billion pounds in 2031 sales, the shares rose as much as 5.6% to their highest level in nearly 25 years. Sheena Berry, a healthcare analyst at Quilter Cheviot, called that outlook a “steady and credible start” for Miels. 5
But the risks are still there. GSK said in February that 2026 revenue should grow 3% to 5%, slower than in 2025, while sales in vaccines and general medicines were expected to be flat or down slightly. Reuters reported that Barclays analysts viewed that forecast as a little below consensus, mainly because of foreign-exchange pressure. 5
For now, the stock looks stuck between support from capital returns and caution over the next leg of growth. Monday’s close left GSK well below its 52-week high of 2,282 pence even as the FTSE 100 rose 0.55%, suggesting investors want the next commercial or pipeline catalyst, not just a steady buyback rhythm. 1
